DR. STANLEY N. COHEN, M.D.
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California C030563
Category
Osteopathic Medicine
Type
Clinical Pharmacology
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 723-5315
(650) 725-1536 (Fax)
(650) 725-1536 (Fax)
Professional information
Modulating Sos Response Induction By Antimicrobial Agents
US Patent:
7592154, Sep 22, 2009
Filed:
Aug 1, 2006
Appl. No.:
11/498208
Inventors:
Christine A. Miller - San Francisco CA, US
Ronen Mosseri - Tel Aviv, IL
Stanley N. Cohen - Stanford CA, US
Ronen Mosseri - Tel Aviv, IL
Stanley N. Cohen - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12Q 1/18, C12Q 1/02
US Classification:
435 32, 435 29
Abstract:
Compositions and methods are provided for the use of SOS pathway targeted agents in antimicrobial formulations. The innate sensitivity of bacteria to antibiotics is increased by disrupting a mechanism that normally activates the bacterial SOS response or by inhibiting steps in the SOS response pathway itself. SOS response induction can result from exposure of bacteria to certain antibiotics, including β-lactam antibiotics and other agents that affect cell wall synthesis. By transiently delaying bacterial cell division, SOS response induction interferes with bacterial killing by ordinarily lethal concentrations of these drugs A pharmaceutical composition comprising an SOS targeted agent is administered to a patient suffering from a microbial infection, in combination with an antibiotic that induces an SOS response. The identification of the SOS pathway as a target for modulating antibiotic action provides a basis for further therapeutic development, through screening assays designed to detect molecules or genes that act on these pathways.
Methods And Compositions For Homozygous Gene Inactivation Using Collections Of Pre-Defined Nucleotide Sequences Complementary Chromosomal Transcripts
US Patent:
2007024, Oct 18, 2007
Filed:
Jan 25, 2005
Appl. No.:
10/582050
Inventors:
Quan Lu - Mountain View CA, US
Stanley Cohen - Stanford CA, US
Stanley Cohen - Stanford CA, US
International Classification:
A61K 31/00, C07H 21/00, C12N 15/00, C12N 5/00, C12Q 1/68
US Classification:
514001000, 435254100, 435320100, 435325000, 435375000, 435410000, 435006000, 536023100
Abstract:
Methods and compositions for performing homozygous gene inactivation assays are provided. A feature of the subject methods is the use of a library of constructs that synthesize predefined nucleic acids, where each constituent predefined nucleic acid of the library is of known sequence that corresponds to a sequence of a chromosomal transcript, e.g., where a representative embodiment of a predefined nucleic acid is an expressed sequence tag (i.e., EST). In certain embodiments, the subject libraries are produced using an amplification protocol that preserves the sequence representation profile of the template nucleic acids. The subject methods and compositions find use in a variety of different applications, including the identification of novel diagnostic and therapeutic genetic targets.
Mammalian Tumor Susceptibility Genes And Their Uses
US Patent:
5891668, Apr 6, 1999
Filed:
Jun 13, 1996
Appl. No.:
8/670274
Inventors:
Limin Li - Stanford CA
Stanley N. Cohen - Stanford CA
Stanley N. Cohen - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12P 2102, C12N 1500, C12N 1512
US Classification:
435 691
Abstract:
TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene.
Mammalian Tumor Susceptibility Genes And Their Uses
US Patent:
5807995, Sep 15, 1998
Filed:
Nov 25, 1997
Appl. No.:
8/977818
Inventors:
Stanley N. Cohen - Stanford CA
Limin Li - Stanford CA
Limin Li - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07K 1447
US Classification:
530350
Abstract:
TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene.
Selective Reduction Of The Deleterious Activity Of Extended Tri-Nucleotide Repeat Containing Genes
US Patent:
2013031, Nov 28, 2013
Filed:
Dec 8, 2011
Appl. No.:
13/988605
Inventors:
Tzu-Hao Cheng - Taipei City, TW
Chia-Rung Liu - Tainan City, TW
Tzu-Han Wang - Taipei City, TW
Stanley N. Cohen - Stanford CA, US
Chia-Rung Liu - Tainan City, TW
Tzu-Han Wang - Taipei City, TW
Stanley N. Cohen - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
NATIONAL YANG-MING UNIVERSITY - Taipei
NATIONAL YANG-MING UNIVERSITY - Taipei
International Classification:
A61K 31/713
US Classification:
514 44 A, 435375, 435 71, 435 611, 435 612
Abstract:
Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).
Methods And Compositions For Treating A Subject Having An Anthrax Toxin Mediated Condition
US Patent:
7838252, Nov 23, 2010
Filed:
Feb 16, 2006
Appl. No.:
11/356740
Inventors:
Stanley N. Cohen - Stanford CA, US
Wensheng Wei - Stanford CA, US
Wensheng Wei - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12Q 1/68, G01N 33/53, G01N 33/567
US Classification:
435 72, 4241301, 4241431, 4241411, 4241521, 435 721
Abstract:
Methods and compositions for treating a subject for an anthrax toxin mediated disease condition are provided. Aspects of the subject methods include administering to a subject an effective amount of an agent that inhibits cellular internalization of an anthrax toxin, e. g. , such as a LRP6 modulatory agent. Also provided are active agents suitable for use in the subject methods, as well as pharmaceutical preparations thereof.
Methods And Compositions For Identifying Cellular Genes Exploited By Viral Pathogens
US Patent:
2008017, Jul 24, 2008
Filed:
Aug 2, 2007
Appl. No.:
11/890314
Inventors:
Stanley N. Cohen - Stanford CA, US
Daniel Rock - Stanford CA, US
Annie Chang - Stanford CA, US
Yanan Feng - Stanford CA, US
Laszlo Zsak - Stanford CA, US
Maria Elisa Piccone - Old Say Brook CT, US
Daniel Rock - Stanford CA, US
Annie Chang - Stanford CA, US
Yanan Feng - Stanford CA, US
Laszlo Zsak - Stanford CA, US
Maria Elisa Piccone - Old Say Brook CT, US
International Classification:
A61K 47/00, C40B 30/06, C40B 40/02, A01K 67/027, A61P 43/00
US Classification:
514789, 506 10, 506 14, 800 13
Abstract:
Methods and compositions for rapidly identifying CGEPs required for viral infection of mammalian cells are provided. Also provided are methods of inhibiting viral infection of mammalian cells by inhibiting the activity of one or more CGEPs (e.g., as identified in accordance with methods of the invention) in the cells. Aspects of the invention further include specifically identified CGEPs implicated in mammalian cell infection of specific viruses, e.g., African Swine Fever Virus and Foot and Mouth Virus, and methods of modulating their activity to achieve viral resistance.
Txr1 And Enhanced Taxane Sensitivity Based On The Modulation Of A Pathway Mediated Thereby
US Patent:
2007020, Sep 6, 2007
Filed:
Feb 16, 2006
Appl. No.:
11/357728
Inventors:
Chih Lih - Palo Alto CA, US
Stanley Cohen - Stanford CA, US
Stanley Cohen - Stanford CA, US
International Classification:
A01K 67/027, C12Q 1/68, A61K 48/00, A61K 31/337, C12P 21/06, C07K 14/705, C07K 16/30
US Classification:
800014000, 514449000, 514044000, 435006000, 435069100, 435325000, 435320100, 530350000, 530388800, 536023500
Abstract:
Methods and compositions for enhancing taxane sensitivity are provided. Aspects of the subject methods include administering to a subject a txr1 pathway modulatory agent in conjunction with a taxane. Also provided are txr1 polypeptides and nucleic acids encoding the same. The subject methods and compositions find use in a variety of different applications.
Assay For Tsg101 As Inhibitors Of Hiv Production
US Patent:
7494767, Feb 24, 2009
Filed:
May 21, 2002
Appl. No.:
10/478753
Inventors:
Carol Carter - Huntington NY, US
Arthur Goff - Miller Place NY, US
Lorna Ehrlich - Shoreham NY, US
Stanley N. Cohen - Stanford CA, US
Arthur Goff - Miller Place NY, US
Lorna Ehrlich - Shoreham NY, US
Stanley N. Cohen - Stanford CA, US
Assignee:
Functional Genetics, Inc. - Gaithersburg MD
International Classification:
C12Q 1/00, C12Q 1/70, C12Q 1/68, G01N 33/53
US Classification:
435 4, 435 5, 435 6, 435 71
Abstract:
The present invention provides methods for identifying peptides in a mammalian. Tsg101 protein that binds to the PTAPP (SEQ ID NO: 3) motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.
Tsg101 As Inhibitor Of Hiv Production
US Patent:
2005000, Jan 13, 2005
Filed:
Sep 18, 2003
Appl. No.:
10/666997
Inventors:
Carol Carter - Huntington NY, US
Arthur Goff - Miller Place NY, US
Lorna Ehrlich - Shoreham NY, US
Stanley Cohen - Stanford CA, US
Arthur Goff - Miller Place NY, US
Lorna Ehrlich - Shoreham NY, US
Stanley Cohen - Stanford CA, US
International Classification:
C12Q001/70, A61K038/17
US Classification:
514012000, 435005000
Abstract:
The present invention provides methods for identifying peptides in a mammalian. Tsg101 protein that binds to the PTAPP motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.